Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Novel drug for dry age related macular degeneration

Project description

Novel AMD treatment development

Dry age-related macular degeneration (AMD) is a significant cause of vision loss, and since there is currently no available treatment, early intervention can help slow its progression, thereby preserving both vision and quality of life. OphtiMedRx, a start-up focused on ophthalmic drug development and led by a team of accomplished female physicians and scientists, is actively working on a novel drug for the treatment of AMD. This drug candidate specifically targets cell senescence and can be administered via intravitreal (IVT) injection in a clinical setting without requiring hospitalisation. Phase I clinical trials are scheduled for late 2024. The EU-funded OPTM.RX project will allocate this grant towards consultant fees, a specialised regulatory firm, and FDA/EMA fees.

Objective

OphtiMedRx is an ophthalmic drug development start-up company led by a team of exceptional women physicians and scientists led by Dr. Dana Rabinovich. OphtiMedRx is developing a novel drug for treating dry age-related macular degeneration (AMD), a leading cause of vision loss. There is no available treatment for dry AMD, which affects 8.7% of the population and a further 2 million diagnosed yearly. The occurrence of AMD steadily increases with age, affecting 2% of the population at age 40 and 20% of people over 75. Our drug candidate, delivered by intravitreal (IVT) injection in a clinic setting without hospitalization, targets cellular aging, termed cell senescence. Our product addresses the underlying cause of dry AMD, allowing for early intervention. Targeting the disease at early stages will halt, or significantly slow, dry AMD progression, preserving vision and maintaining quality of life. We are currently performing preclinical R&D studies and plan to be ready for Phase I clinical trials by the end of 2024. A crucial step toward clinical trials is conducting a pre-Investigational New Drug (IND) meeting with the FDA and a scientific advice meeting with EMA officials. These meetings are an opportunity to gain the agency’s feedback on the design of the proposed nonclinical and clinical studies. Additionally, these meetings will help us determine the budget and timeline for transitioning towards phase I clinical trials, as well as set a goal for the next fundraising round. The financial contribution of this grant will go towards consultant fees, a specialized regulatory firm, and FDA/EMA fees. In addition, as a new CEO, I would greatly benefit from the mentoring and coaching provided by EIC’s Business Acceleration Services, which will help me improve my professional skill set, particularly in investor relations, and assist me with my various management and leadership challenges.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIE-2022-SCALEUP-02

See all projects funded under this call

Coordinator

OPTM.RX LTD
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 75 000,00
Address
BARNEA ST 4
1290000 Katzrin
Israel

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0